GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$7.55
+0.37 (+5.15%)
Open$7.12
Previous Close$7.18
Day High$7.56
Day Low$7.10
52W High$9.42
52W Low$5.44
Volume—
Avg Volume106.8K
Market Cap710.43M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+296.3% upside
Current
$7.55
$7.55
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 106.32M | 231.94M | 230.03M |
| Net Income | 4.58M | -34,891,358 | -29,454,556 |
| Profit Margin | 4.3% | -15.0% | -12.8% |
| EBITDA | 12.74M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +428.5% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |